Hester Biosciences Share Price

Hester Biosciences Limited is one of the leading and pioneering animal healthcare companies in India. The Company was incorporated in April, 1987 and is engaged in manufacturing of Poultry vaccines and Large Animal Vaccines and trading of Poultry and Large animal and Petcare health products having its manufacturing set up at Meda Adraj Village, Mehsana District, Gujarat. The Company built a presence in several regions of Africa and in numerous nations, including Vietnam, Indonesia, Nepal, and Bangladesh. The products and services included over 50 vaccines and 70+ health products. In addition, it offers a vast selection of pharmaceuticals, feed supplements, and disinfectants for poultry and large animals.The Company markets and distributes veterinary and pharmaceutical products like animal health products, poultry vaccines, poultry diagnostic, laboratory kits and reagents. It markets the veterinary products of many international companies including Ghen Corporation, Japan Maine Biological Laboratories, US Idexx Corporation, US International Diagnostic Systems Corporation, US Biogal Galed Laboratories, Israel and Kemin Europa, Belgium.The companys own production of veterinary vaccines (in Vials) is expected to commence soon. HPL has technical collaborations with Maine Biological Laboratories and Ghen Corporation.During 199697, company successfully implemented veterinary vaccine and commercial production has begun.The company received licenses for producing 10 additional poultry vaccines. It signed a manufacturing agreement with Sinsui Inc for producing poultry vaccines.In 2003, Hester was appointed as the exclusive Indian distributor by BIOPHARM of Czech Republic, for their coccidiosis vaccine LIVACOX.Hester commenced business with Merial in the 3rd quarter of the financial year by importing poultry vaccines from them in 200405 and therefore, name of Company was changed from HESTER PHARMACEUTICALS LIMITED to HESTER BIOSCIENCES LIMITED. The Company embarked on an expansion program, to increase its capacity from 1200 million doses to 4800 million doses, which was commenced in January 2006. The expansion project and the new expanded capacity went onstream in March 2007. The distribution network within India was made functional with company managed depots at Pune, Bangalore, Coimbatore, Hyderabad and Chandigarh, having stateofart cold store facilities to maintain the cold chain. Distribution costs were further cut by embarking on the use of company owned refrigerated vans for deliveries all across India. In January 2010, the company relaunched the freeze dried MD Vaccine after 5 years. A JV was setup in Nepal to facilitate manufacture of specific animal vaccines for international markets in 2011 for a project which costed Rs 15 crores. New technology was acquired. The Company signed a technology transfer agreement with Indian Veterinary Research Institute for acquiring technology to manufacture PPR and Sheep Pox vaccines in 2011. Company relaunched the bivalent Mareks Disease Live vaccine for the poultry, containing HVT SB1 strains in 201213. It operationalised large animal vaccines division in Mar 15. During the financial year 201415, Gujarat Agrofarm Limited became a wholly owned subsidiary of the Company. During financial year 201516, three wholly owned subsidiary Companies namely Gujarat Agrofarm Limited, Diavetra Lifesciences Private Limited and Hester Biosciences (Mauritius) Limited got merged with Company through a Scheme of Arrangement effective on 8 December 2015. Accordingly, the Company allotted and listed its 65 Equity Shares pursuant to Scheme of Arrangement vide order passed by Honble High Court of Gujarat dated 8 December 2015 and the said Shares were listed at NSE Limited and BSE Limited in March, 2016. Leruarua Vetcare (Proprietary) Limited, incorporated in Botswana became an Associate Company with 49% stake of the Company and Innoves Animal Health Private Limited ceases to be an Associate Company due to transfer of shareholding of the Company in FY 201516.The Nepal unit completed trial operations and began commercial manufacturing in November, 2016. Leruarua Vetcare (Proprietary) Limited, Botswana ceases to be an Associate Company due to buyback of entire shareholding by the Associate Company during the FY 201617. The Company held 65% stake in subsidiary Company, Hester Biosciences Nepal Private Limited (HBNPL) and consequently, HBNPL became a subsidiary of Hester Biosciences Limited (Parent Company) during FY 201617.During the year 201718, Company acquired 54.80% in the capital of Texas Laboratories, a firm having a business place at Mehsana Distt. of Gujarat. In June 2017, Texas Laboratories converted into Private Limited Company namely, Texas Lifesciences Private Limited. Further, the Company incorporated 100% whollyowned subsidiary, Hester Biosciences Africa Limited in Tanzania. During the year 201819, Hester Biosciences Limited incorporated 100% whollyowned subsidiary Hester Biosciences Kenya Limited in Kenya. The Company commissioned the vaccine manufacturing plant at Tanzania in 2021. It launched the Petcare Division in 2022.In FY 2022, Company acquired 50% stake in Tanzania based Thrishool Exim Limited, company of vaccines and animal health products in Tanzania. It launched 3 products for antiinfective, specialty nutrition, parasiticides and grooming. It commenced production of Newcastle Disease and Gumboro vaccines for poultry, and PPR and Contagious Bovine Pleuropneumonia (CBPP) vaccines for large animals.The Company launched new feed supplements and disinfectants, which started to gain traction in the market in FY25.Company launched a set of new products to its poultry health and hygiene portfolio including the Silvectant, Hestbac, Hestflora, AmmoStop, etc. Besides these, an INACTIVATED H9N2 Vaccine was introduced for protection against low pathogenic avian influenza in FY26. The Animal Healthcare division has been expanded with the launch of key products like ICEFT RTU, Bovitone HQ10 Inomilk Gel during 2026.

For the full year FY2026–2027, revenue reached ₹342.28 crore and profit touched at ₹51.11 crore.